4D Molecular Therapeutics Files 8-K
Ticker: FDMT · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
4D Molecular Therapeutics filed an 8-K on Feb 28, 2025, reporting on financials.
AI Summary
On February 28, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that 4D Molecular Therapeutics is providing updates on its financial condition and results of operations to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial condition and results of operations, without immediate news of significant events.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- February 28, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company is 4D Molecular Therapeutics Inc.
In which state was 4D Molecular Therapeutics, Inc. incorporated?
4D Molecular Therapeutics, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 5858 Horton Street #455, Emeryville, California, 94608.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for 4D Molecular Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding 4D Molecular Therapeutics, Inc. (FDMT).